3-iodothyronamine and Disease-Models--Animal

3-iodothyronamine (T1AM) and the recently developed analog SG-2 are rapidly emerging as promising multi-target neuroprotective ligands able to reprogram lipid metabolism and to produce memory enhancement in mice. To elucidate the molecular mechanisms underlying the multi-target effects of these novel drug candidates, here we investigated whether the modulation of SIRT6, known to play a key role in reprogramming energy metabolism, might also drive the activation of clearing pathways, such as autophagy and ubiquitine-proteasome (UP), as further mechanisms against neurodegeneration. We show that both T1AM and SG-2 increase autophagy in U87MG cells by inducing the expression of SIRT6, which suppresses Akt activity thus leading to mTOR inhibition. This effect was concomitant with down-regulation of autophagy-related genes, including Hif1α, p53 and mTOR. Remarkably, when mTOR was inhibited a concomitant activation of autophagy and UP took place in U87MG cells. Since both compounds activate autophagy, which is known to sustain long term potentiation (LTP) in the entorhinal cortex (EC) and counteracting AD pathology, further electrophysiological studies were carried out in a transgenic mouse model of AD. We found that SG-2 was able to rescue LTP with an efficacy comparable to T1AM, further underlying its potential as a novel pleiotropic agent for neurodegenerative disorders treatment.

Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Autophagosomes; Autophagy; Cell Line, Tumor; Disease Models, Animal; Entorhinal Cortex; Gangliosides; Gene Expression Regulation; Humans; Long-Term Potentiation; Mice, Transgenic; Neuroprotective Agents; Sirtuins; Thyronines; TOR Serine-Threonine Kinases

This study aims to show how 3-iodothyronamine (T1AM) protects against spinal cord injury (SCI) in rats. We randomly divided adult female Sprague-Dawley rats (N=54) into three equal groups: (1) untreated control (n=18) (2) T1AM (n=18) (3) T1AM+EPPTB (n=18). The clamp method was used to produce SCI at the T10 segment, and the following data were collected 3, 5, and 7 days after the injury plus treatment. The mean BBB scores of both the control and T1AM+EPPTB groups were 1.5±0.5, 3.5±0.5, and 4.5±0.5 on days 3, 5, and 7 after SCI, respectively, whereas those for the T1AM group were 3.3±0.5, 5.3±0.5, and 7.5±0.5, a significant difference from the first two groups mentioned on each day (all

Topics: Animals; Apoptosis; Disease Models, Animal; Female; In Situ Nick-End Labeling; Injections, Intraperitoneal; Motor Activity; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Spinal Cord Injuries; Thyronines

3-iodothyronamine (T1AM) and its oxidative product, 3-iodotyhyroacetic acid (TTA1A), are known to stimulate learning and induce hyperalgesia in mice. We investigated whether i)TA1 may be generated in vivo from T1AM, ii) T1AM shares with TA1 the ability to activate the histaminergic system. Tandem mass spectrometry was used to measure TA1 and T1AM levels in i) the brain of mice following intracerebroventricular (i.c.v.) injection of T1AM (11μgkg(-1)), with or without pretreatment with clorgyline, (2.5mgkg(-1) i.p.), a monoamine oxidase inhibitor; ii) the medium of organotypic hippocampal slices exposed to T1AM (50nM). In addition, learning and pain threshold were evaluated by the light-dark box task and the hot plate test, respectively, in mice pre-treated subcutaneously with pyrilamine (10mgkg(-1)) or zolantidine (5mgkg(-1)), 20min before i.c.v. injection of T1AM (1.32 and 11μgkg(-1)). T1AM-induced hyperalgesia (1.32 and 11μgkg(-1)) was also evaluated in histidine decarboxylase (HDC(-/-)) mice. T1AM and TA1 brain levels increased in parallel in mice injected with T1AM with the TA1/T1AM averaging 1.7%. Clorgyline pre-treatment reduced the increase in both T1AM and TA1. TA1 was the main T1AM metabolite detected in the hippocampal preparations. Pretreatment with pyrilamine or zolantidine prevented the pro-learning effect of 1.32 and 4μgkg(-1) T1AM while hyperalgesia was conserved at the dose of 11μgkg(-1) T1AM. T1AM failed to induce hyperalgesia in HDC(-/-) mice at all the doses. In conclusion, TA1 generated from T1AM, but also T1AM, appears to act by modulating the histaminergic system.

Topics: Animals; Avoidance Learning; Behavior, Animal; Biotransformation; Disease Models, Animal; Hippocampus; Histamine; Histamine Antagonists; Histidine Decarboxylase; Hyperalgesia; Injections, Intraventricular; Male; Mice, 129 Strain; Mice, Knockout; Monoamine Oxidase Inhibitors; Oxidation-Reduction; Pain Threshold; Signal Transduction; Tandem Mass Spectrometry; Thyroid Hormones; Thyronines